Skip to main content

Table 1 The association between BRAF V600 mutation status and clinicopathologic characteristics

From: BRAF V600 mutation profiling in primary skin nodular melanoma in Indonesia: an analysis using high resolution pyrosequencing

 BRAF (+)BRAF (−)p value**
Age, mean ± SD*60.67 ± 15.8160.67 ± 13.491.000
Age category, n (%)
 < 65 years13 (33.33)10 (25.64)0.469
 ≥ 65 years8 (20.51)8 (20.51) 
Sex, n (%)
 Male8 (20.51)9 (23.08)0.336
 Female13 (33.33)9 (23.08) 
Anatomic location, n (%)
 Extremity14 (35.90)15 (38.46)0.207
 Central7 (17.95)3 (7.69) 
Lymph node metastasis, n (%)
 Present10 (25.64)8 (20.51)0.549
 Absent11 (28.21)10 (25.64) 
Tumor thickness, n (%)
 ≤ 4 mm1 (2.56)3 (7.69)0.246
 > 4 mm20 (51.28)15 (38.46) 
Ulceration, n (%)
 Present10 (25.64)12 (30.77)0.192
 Absent11 (28.21)6 (15.38) 
Mitotic index, mean ± SD*25.82 ± 18.7723.22 ± 16.080.648
Mitotic index category, n (%)
 ≥ 20%12 (30.77)10 (25.64)0.588
 < 20%9 (23.08)8 (20.51) 
Necrosis, n (%)
 Present17 (43.59)11 (28.21)0.570
 Absent4 (10.26)7 (17.95) 
Lymphovascular invasion, n (%)
 Present9 (23.08)4 (10.26)0.153
 Absent12 (30.77)14 (35.90) 
Tumor-infiltrating lymphocytes, n (%)
 Present13 (33.33)13 (33.33)0.368
 Absent8 (20.51)5 (12.82) 
  1. *SD standard deviation
  2. **p value < 0.05 was considered significant
\